Analyst Kyle Mikson CFA from Canaccord Genuity maintained a Hold rating on Illumina and keeping the price target at $150.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kyle Mikson CFA has given his Hold rating due to a combination of factors tied to Illumina’s competitive and product outlook. He acknowledges that Roche’s new AXELIOS platform looks commercially viable and is priced between Illumina and low-cost rivals, but he also highlights that the system is still in an early phase with unresolved questions around workflow integration, assay revalidation, and accuracy trade-offs that will influence near-term adoption.
At the same time, Illumina is concentrating on incremental NovaSeq X enhancements instead of introducing a new high-throughput system, a strategy Mikson views as stabilizing but not transformative for growth. His analysis indicates that Roche’s entry is unlikely to significantly erode Illumina’s valuation in most scenarios, yet the evolving landscape in clinical sequencing and the need for clearer evidence of re-accelerating revenue lead him to stay neutral. As a result, he reiterates a Hold rating and maintains a $150 price target while waiting for greater visibility on competitive dynamics and Illumina’s growth trajectory.